Last $108.36 USD
Change Today -0.06 / -0.06%
Volume 1.0M
As of 8:10 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

biomarin pharmaceutical inc (BMRN) Snapshot

Open
$107.21
Previous Close
$108.42
Day High
$108.53
Day Low
$106.07
52 Week High
02/26/15 - $111.89
52 Week Low
04/15/14 - $55.04
Market Cap
17.2B
Average Volume 10 Days
1.2M
EPS TTM
$-1.21
Shares Outstanding
159.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOMARIN PHARMACEUTICAL INC (BMRN)

biomarin pharmaceutical inc (BMRN) Details

BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease; and Vimizim, an enzyme replacement therapy to treat MPS IVA, a lysosomal storage disorder. The company also develops PEG-PAL, an enzyme substitution therapy that is under Phase III clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trial for Pompe disease, a glycogen storage disorder; BMN-673, a poly ADP-ribose polymerase inhibitor that is in Phase III clinical trial to treat germline BRCA breast cancer; and BMN-111, a C-natriuretic peptide that is under Phase I clinical trial to treat achondroplasia. In addition, it develops BMN 190, a recombinant human tripeptidyl peptidase-1 in Phase 1 clinical trial to treat late-infantile neuronal ceroid lipofuscinosis, a form of Batten Disease; BMN 270, an AAV-factor VIII vector to treat hemophilia A; and BMN 250, a novel fusion of alpha-N-acetyglucosaminidase to treat MPS IIIB. The company sells its Naglazyme, Kuvan, and Firdapse products to specialty pharmacies and end-users, such as hospitals and foreign government agencies, which act as retailers; and Naglazyme products to distributors and pharmaceutical wholesalers. It has a collaboration agreement with Genzyme Corporation; and an agreement with Merck Serono S.A. BioMarin Pharmaceutical Inc. was founded in 1996 and is headquartered in San Rafael, California.

biomarin pharmaceutical inc (BMRN) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $868.8K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $457.8K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $631.9K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $409.6K
Executive Vice President of Technical Operati...
Total Annual Compensation: $414.4K
Compensation as of Fiscal Year 2013.

biomarin pharmaceutical inc (BMRN) Key Developments

BioMarin Pharmaceutical Inc. Announces Unaudited Consolidated Financial Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Year Ending December 31, 2015

BioMarin Pharmaceutical Inc. announced unaudited consolidated financial results for the fourth quarter and full year ended December 31, 2014. For the quarter, Non-GAAP net loss declined to $11.4 million or $0.08 per basic and diluted share compared to $15.8 million or $0.11 per basic and diluted share for the fourth quarter of 2013. GAAP net loss was $69.8 million or $0.47 per basic and diluted share compared to $62.0 million or $0.44 per diluted share for the fourth quarter of 2013. Total revenues were $230,854,000 against $146,873,000 a year ago. Loss from operations was $58,756,000 against $52,310,000 a year ago. Loss before income taxes was $65,737, 000 against $59,375,000 a year ago. LBITDA was $44.6 million against $43.9 million a year ago. For the year, non-GAAP net loss was reduced to $25.9 million or $0.18 per basic and diluted share compared to $40.4 million or $0.30 per diluted share for the year ended December 31, 2013. GAAP net loss was $134.0 million or $0.92 per basic and diluted share compared to $176.4 million or $1.28 per basic and diluted share for the year ended December 31, 2013. The company delivered another year of strong results from five commercialized products. Total revenues were $751,040,000 against $548,485,000 a year ago. Loss from operations was $92,891,000 against $156,007,000 a year ago. Loss before income taxes was $124,868, 000 against $176,503,000 a year ago. LBITDA was $48.4 million against $132.2 million a year ago. The company provided earnings guidance for the year ending December 31, 2015. For the year, the company expects total revenues to be between $840 million to $870 million, non - GAAP net loss of $130 million to $170 million, GAAP net loss of $360 million to $400 million and LBITDA of $318.9 million to $358.9 million.

Investors Reportedly Eyes Stake In PTCT

PTC Therapeutics, Inc. (NasdaqGS:PTCT) is exploring a potential sale amid takeover interest from Shire plc (LSE:SHP) and BioMarin Pharmaceutical Inc. (NasdaqGS:BMRN), according to people familiar with the matter. PTCT is working with financial advisers as it weighs strategic alternatives, said the sources, who asked not to be named because the matter is private. Representatives for could not be reached for comment. Representatives for Shire and BioMarin declined to comment. Shire Plc could be interested in acquiring PTC Therapeutics to add to its portfolio of rare disease drugs, the sources added.

BioMarin Pharmaceutical Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015

BioMarin Pharmaceutical Inc. Presents at SunTrust Robinson Humphrey Biotechnology and Pharmaceutical One-on-One Orphan Drug Day, Feb-23-2015 . Venue: JW Marriott Essex House, 160 Central Park South, b/w 6th & 7th Avenue, New York, New York, United States.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BMRN:US $108.36 USD -0.06

BMRN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alkermes PLC $72.80 USD +1.33
Amarin Corp PLC $1.54 USD 0.00
Jazz Pharmaceuticals PLC $176.30 USD +1.88
Spectrum Pharmaceuticals Inc $6.06 USD -0.10
Vertex Pharmaceuticals Inc $123.52 USD +3.35
View Industry Companies
 

Industry Analysis

BMRN

Industry Average

Valuation BMRN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.4x
Price/Book 10.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 20.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOMARIN PHARMACEUTICAL INC, please visit www.biomarinpharm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.